Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Roberto Mignone’s Bridger Management Boosts Its Position in $CRME

Roberto Mignone’s Bridger Management boosts its position in Cardiome Pharma Corp (CRME). According to the 13G disclosed on October 13th, Bridger Management now has 3.39 million shares of CRME in its portfolio, corresponding to a 5.5% stake of the stock. As is shown in the latest 13F, Bridger Management was one of the five hedge funds which retained positions in CRME in the second quarter. The firm had 2.14 million CRME shares, or 3.89% stake at that time. So this is a nearly 50% expansion in Bridger Management’s position. CRME has lost about 50% so far, and has just rallied from its 2-year low on October 4th. Since CRME’s daily trading volume is about 200 thousand, it’s possible that Bridger Management entered at about $3.5 in late September. Now the stock is priced at $3.57, and outsiders may choose to imitate Bridger Management’s transaction at this point.

BRIDGER MANAGEMENT

According to Insider Monkey’s hedge fund tracking list, five hedge funds reported CRME in their positions in the second quarter. Phill Gross and Robert Atchinson’s Adage Capital Management had a much larger position with 6.70 million shares, which gave them a more than 10% stake. Julian Robertson’s Tiger Management had 2.53 million shares, giving a 4% stake. George Soros also had a small position for 13 thousand shares in CRME.

Bridger Management is managed by Roberto Mignone, who graduated from Harvard Business School and joined John Griffin at Blue Ridge Capital. Right before his 29th birthday in July 2000, he launched Bridger Management which now manages about $2 Billion. He charges a 1.5 percent management fee and 20 percent incentive fee. He believes fund size is a drag on the performance of a long/short fund manager, so he has no desire to run a much bigger fund than what he is currently running. Roberto Mignone’s Bridger Management keeps their returns extremely secret. They do extensive analysis and follow a long/short strategy. (You can see the rest of his profile here)

Cardiome Pharma Corp. is a life sciences company. It engages in developing proprietary drugs for cardiovascular and other diseases. It also has clinical programs and pre-clinical projects. The company has collaboration and license agreement with Merck & Co., Inc. and Astellas Pharma US, for vernakalant-related projects. Cardiome Pharma Corp. was founded in 1986 and is based in Vancouver, Canada.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!